Organon & Co. Stock News

Organon & Co (OGN) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)

Organon, a pharmaceutical company, has a diverse portfolio of products in women's health and biosimilars. The company has faced challenges in its women's health segment but expects a turnaround in its

Investors have different approaches to stock dividends. Some have no interest in current income and would prefer companies to focus on growing their businesses, rather than distributing cash to shareh

Organon's stock has declined 32% since September, making it one of the worst performers in healthcare. The company reported mixed financial results, with 1% growth in product sales and a decline in to

Jenny Harrington, Gilman Hill Asset Management CEO, discusses her top dividend picks for 2024.

Organon is a global healthcare company focused on women's health, with a diverse portfolio of prescription therapies and medical devices. OGN stock has been on a downward trend due to declining sales

It has been over two years since Organon spun off from Merck. Lack of growth and deteriorating financials haven't given investors much of a reason to be bullish thus far.

Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D C

The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close look at the company's debt and how I think the sit

Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for income-oriented investors. The company has a stabl

The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Con

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar drugs, sending the healthcare firm's shares up about

Organon, a global healthcare company, is a buy for value and income investors due to its strong growth in biosimilars business and 5.5% dividend yield. Despite a 20% YoY decline in adjusted EBITDA, th

The "Halftime Report" traders give their top picks to watch for the second half.